PeptiDream Inc. (4587.T)
JPY 1883.0
(-0.4%)
JPY 1883.0
(-0.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 7.37 Billion JPY | -12.17% |
| 2022 | 9.02 Billion JPY | 118.7% |
| 2021 | 5 Billion JPY | -41.28% |
| 2020 | 7.56 Billion JPY | 775.12% |
| 2019 | -1.26 Billion JPY | -130.77% |
| 2018 | 4.1 Billion JPY | 19.67% |
| 2017 | 3.42 Billion JPY | 27.61% |
| 2016 | 2.68 Billion JPY | -0.44% |
| 2015 | 2.69 Billion JPY | 80.17% |
| 2014 | 1.49 Billion JPY | 444.24% |
| 2013 | 275.1 Million JPY | 29.05% |
| 2012 | 213.17 Million JPY | 811.75% |
| 2011 | 23.38 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 26.3 Billion JPY | 8434.55% |
| 2024 Q1 | -461.78 Million JPY | -157.58% |
| 2023 Q1 | 313.37 Million JPY | -96.8% |
| 2023 Q2 | -78.53 Million JPY | -125.06% |
| 2023 Q3 | 8.45 Billion JPY | 10860.29% |
| 2023 Q4 | 637.95 Million JPY | -92.45% |
| 2023 FY | - JPY | -12.17% |
| 2022 FY | - JPY | 118.7% |
| 2022 Q4 | 9.8 Billion JPY | 411.89% |
| 2022 Q2 | 919 Million JPY | 197.31% |
| 2022 Q1 | -944.37 Million JPY | -1216.15% |
| 2022 Q3 | 1.91 Billion JPY | 108.38% |
| 2021 Q4 | 84.61 Million JPY | -97.71% |
| 2021 FY | - JPY | -41.28% |
| 2021 Q2 | -139.32 Million JPY | -122.65% |
| 2021 Q3 | 3.68 Billion JPY | 2748.18% |
| 2021 Q1 | 615.01 Million JPY | -89.97% |
| 2020 Q1 | -338.95 Million JPY | 0.0% |
| 2020 FY | - JPY | 775.12% |
| 2020 Q4 | 6.13 Billion JPY | 16935.77% |
| 2020 Q3 | -36.43 Million JPY | -102.02% |
| 2020 Q2 | 1.8 Billion JPY | 632.07% |
| 2019 Q1 | 249.63 Million JPY | -69.45% |
| 2019 Q2 | 3.02 Billion JPY | 1113.59% |
| 2019 FY | - JPY | -130.77% |
| 2019 Q3 | -287.55 Million JPY | -109.49% |
| 2018 Q2 | 4.34 Billion JPY | 1567.77% |
| 2018 Q3 | 5.07 Million JPY | -99.88% |
| 2018 Q1 | -295.8 Million JPY | -208.32% |
| 2018 Q4 | 817.03 Million JPY | 16008.79% |
| 2018 FY | - JPY | 19.67% |
| 2017 FY | - JPY | 27.61% |
| 2017 Q4 | 273.07 Million JPY | 130.61% |
| 2017 Q3 | -891.98 Million JPY | -136.7% |
| 2017 Q2 | 2.43 Billion JPY | 1398.37% |
| 2017 Q1 | -187.19 Million JPY | -1465.62% |
| 2016 FY | - JPY | -0.44% |
| 2016 Q3 | 428.24 Million JPY | -59.06% |
| 2016 Q4 | 13.7 Million JPY | -96.8% |
| 2016 Q2 | 1.04 Billion JPY | -13.79% |
| 2016 Q1 | 1.21 Billion JPY | 270.65% |
| 2015 Q3 | 108.58 Million JPY | -92.73% |
| 2015 FY | - JPY | 80.17% |
| 2015 Q2 | 1.49 Billion JPY | 5010.2% |
| 2015 Q1 | -30.42 Million JPY | -139.82% |
| 2015 Q4 | 327.38 Million JPY | 201.5% |
| 2014 Q1 | -13.42 Million JPY | -108.06% |
| 2014 Q4 | 76.38 Million JPY | 268.03% |
| 2014 Q3 | -45.46 Million JPY | -150.81% |
| 2014 Q2 | 89.46 Million JPY | 766.39% |
| 2014 FY | - JPY | 444.24% |
| 2013 FY | - JPY | 29.05% |
| 2013 Q2 | 36.14 Million JPY | 0.0% |
| 2013 Q3 | 32.52 Million JPY | -10.01% |
| 2013 Q4 | 166.53 Million JPY | 412.01% |
| 2012 FY | - JPY | 811.75% |
| 2011 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | -669.862% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | 1611.079% |
| GNI Group Ltd. | 14.48 Billion JPY | 49.091% |
| Linical Co., Ltd. | 1.24 Billion JPY | -491.394% |
| Trans Genic Inc. | 240.95 Million JPY | -2961.216% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 644.015% |
| Soiken Holdings Inc. | -583.2 Million JPY | 1364.744% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 1323.043% |
| AnGes, Inc. | -8.86 Billion JPY | 183.251% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 673.792% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 199.69% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | -5657.735% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 954.7% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 775.598% |
| CanBas Co., Ltd. | 53.65 Million JPY | -13648.227% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 1051.025% |
| RaQualia Pharma Inc. | -111.8 Million JPY | 6697.491% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 708.718% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 634.179% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 482.241% |
| Ribomic Inc. | -1.01 Billion JPY | 828.481% |
| SanBio Company Limited | -4.52 Billion JPY | 263.007% |
| Healios K.K. | -3 Billion JPY | 345.296% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 732.711% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 629.483% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 626.11% |
| StemRIM | -2.03 Billion JPY | 462.995% |
| CellSource Co., Ltd. | 1.3 Billion JPY | -464.592% |
| FunPep Company Limited | -952 Million JPY | 874.796% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 929.925% |
| Stella Pharma Corporation | -723.85 Million JPY | 1118.998% |
| TMS Co., Ltd. | -937 Million JPY | 887.2% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 1051.27% |
| Cuorips Inc. | -518 Million JPY | 1523.95% |
| K Pharma,Inc. | 366.05 Million JPY | -1914.998% |
| Takara Bio Inc. | 8.02 Billion JPY | 8.075% |
| ReproCELL Incorporated | 8.24 Million JPY | -89361.019% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | -8287.797% |
| StemCell Institute Inc. | 534.35 Million JPY | -1280.37% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | -2912.925% |
| CellSeed Inc. | -836.51 Million JPY | 981.76% |